Isabella Ciccone, MPH

New findings suggest that patients with obstructive sleep apnea and excessive daytime sleepiness exhibit distinct endotypic traits that may influence disease severity and symptom expression.

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine discussed findings presented at AAN 2026 on the use of optical coherence tomography in pediatric MS. [WATCH TIME: 8 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

At AAN 2026, the professor of neurology at the University of South Florida discussed findings from the phase 3 NIMBLE trial assessing cemdisiran in generalized myasthenia gravis. [WATCH TIME: 5 minutes]

Data from the phase 2 CELIA study of diranersen will be presented at the 2026 Alzheimer’s Association International Conference (AAIC) 2026, held July 12-15, in London, United Kingdom.

In honor of Stroke Awareness Month, neurologist Firas Bounni, MD, discussed how advanced neuroimaging can guide thrombectomy decision-making beyond standard treatment windows.

H. E. Hinson, MD, MCR, FAAN, discussed how neurology is rapidly evolving toward interventional therapies, prevention-focused care, and adaptive trial designs, based on presentations from AAN 2026.

In honor of Stroke Awareness Month, the medical director for telestroke at Allegheny Health Network discussed how evolving imaging modalities may be reshaping stroke care. [WATCH TIME: 5 minutes]

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 8, 2026.

In honor of Huntington Disease Awareness Month, held annually in May, the director of the Huntington's Disease Center at Northwestern Medicine discussed the design of the INVEST-HD trial.

The director of the Neuromuscular Division at the Medical University of South Carolina shared post hoc CHAMPION-MG trial findings at MDA 2026, suggesting ravulizumab may enable corticosteroid reduction while maintaining or improving clinical outcomes. [WATCH TIME: 4 minutes]

New phase 2 data indicate that dazucorilant may reduce mortality risk in amyotrophic lateral sclerosis, with sustained effects observed through 2 years, although no significant improvement in functional outcomes was reported.

Here's some of what is coming soon to NeurologyLive® this week.

Interim results from the PIVOT-HD extension study suggested dose-dependent effects of votoplam on measures of disease progression in stage 2 Huntington disease compared with a natural history cohort.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 1, 2026.

Catch up on any of the neurology headlines you may have missed in April 2026, compiled into 1 place by the NeurologyLive® team.

Findings from the phase 2 ADDRESS-LC trial, assessing BioVie’s bezisterim in patients with long COVID–related fatigue and cognitive impairment, are anticipated to be reported in the first half of 2026.

Phase 1 data presented at AAN 2026 suggest that investigational siRNA therapy RAG-17 may reduce key disease biomarkers and show early signs of clinical stabilization following a single dose in patients with SOD1-ALS.

New long-term and post hoc data presented at the 2026 AAN Annual Meeting highlighted durable efficacy, safety, and patient-centered outcomes with nipocalimab in antibody-positive generalized myasthenia gravis.

A duo of Baptist Health experts discussed emerging evidence suggesting that hormonal factors, sex-based clinical differences, and social roles contribute to distinct experiences for women with Parkinson disease.

The deputy director at Association of Movement Disorder Advanced Practice Providers (AMDAPP) recapped key themes in movement disorders presented at the 2026 AMDAPP conference. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor in the Department of Chemistry and Biochemistry at University of Nevada, Las Vegas reflected on receiving the first MDA Research Momentum Award at the 2026 MDA Conference. [WATCH TIME: 2 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

At AAN 2026, an associate professor of neurology at University of Washington discussed how delays in antiamyloid treatment initiation for early Alzheimer disease may be driven by real-world factors. [WATCH TIME: 5 minutes]

New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.